RESUMEN
STUDY OBJECTIVE: To compare the characteristics of NMDR induced muscle paralysis in breast cancer patients with and without a history of recent chemotherapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) regimen. DESIGN: This is a non-randomized prospective cohort study. SETTING: Operating room of a university-affiliated teaching hospital. PATIENTS: Out of a total of 50 patients who had undergone mastectomy, 22 patients were allocated to the "Chemo group" and 28 patients to the "Non-Chemo group", based on a valid history of recent chemotherapy. INTERVENTION: After induction of anesthesia with thiopental and cisatracurium, neuromuscular monitoring was started for all patients. MEASUREMENTS: Initially the time to 100% single-twitch (ST) suppression was measured. Then, the time for the appearance of the first response to post-tetanic count (PTC) stimulation, Train-of-Four (TOF) stimulation, and TOF50% were measured consequently. MAIN RESULTS: Time to get STzero was significantly longer in the Chemo group than in the Non-chemo group. Time for the appearance of the first response of PTC and TOF and TOF50% was significantly shorter in the Chemo group than the other group. The mean duration of intense block was 27.66 minutes in the Chemo group versus 42.47 minutes in the Non-chemo group. CONCLUSION: This research demonstrated that in patients having undergone chemotherapy, the effect of NDMRs starts with a longer lag time and finishes earlier too. Thus, these patients are ready for intubation after a longer time. Moreover, we have to repeat cisatracurium injections after shorter intervals to maintain the desired level of blockade.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Atracurio/análogos & derivados , Bloqueo Neuromuscular/métodos , Fármacos Neuromusculares no Despolarizantes/antagonistas & inhibidores , Adulto , Anestesia General/métodos , Atracurio/administración & dosificación , Atracurio/antagonistas & inhibidores , Atracurio/farmacología , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/cirugía , Quimioterapia Adyuvante , Ciclofosfamida/farmacología , Doxorrubicina/farmacología , Esquema de Medicación , Femenino , Fluorouracilo/farmacología , Humanos , Mastectomía , Persona de Mediana Edad , Monitoreo Intraoperatorio/métodos , Terapia Neoadyuvante/métodos , Unión Neuromuscular/efectos de los fármacos , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Fármacos Neuromusculares no Despolarizantes/farmacología , Estudios ProspectivosRESUMEN
Opioids are important for surgical pain control but may not be appropriate for patients with narcotic abuse histories or opioid intolerance. We describe a laparoscopic bilateral inguinal herniorrhaphy performed without perioperative or postoperative narcotics. Postoperative analgesia involves a novel technique using 2 different bupivacaine formulations that act synergistically to avoid lag time and provide extended pain relief during the acute surgical recovery phase.
Asunto(s)
Anestesia Local/métodos , Bupivacaína/administración & dosificación , Bupivacaína/uso terapéutico , Herniorrafia/métodos , Manejo del Dolor/métodos , Dolor Postoperatorio/tratamiento farmacológico , Analgésicos no Narcóticos/administración & dosificación , Analgésicos no Narcóticos/uso terapéutico , Anestesia General/métodos , Anestesia Raquidea , Anestésicos Locales/administración & dosificación , Anestésicos Locales/uso terapéutico , Atracurio/administración & dosificación , Atracurio/análogos & derivados , Sinergismo Farmacológico , Hernia Inguinal/cirugía , Humanos , Laparoscopía , Liposomas , Masculino , Persona de Mediana Edad , Bloqueo Neuromuscular/métodos , Dimensión del Dolor/métodosRESUMEN
PURPOSE: The physical compatibility of cisatracurium with selected drugs during simulated Y-site administration was studied. METHODS: Study drugs were selected based on the lack of physical compatibility data with cisatracurium and their use in intensive care units. Test admixtures were prepared by mixing 2.5-mL samples of varying concentrations of calcium gluconate, diltiazem, esomeprazole, regular insulin, nicardipine, pantoprazole, and vasopressin with either 2.5 mL of normal saline 0.9% (control) or 2.5 mL of cisatracurium (experimental) to simulate a 1:1 Y-site ratio. Drug infusions were prepared at the maximum concentrations used clinically. Physical compatibility of the admixtures was determined by visual and turbidimetric assessments performed in triplicate immediately after mixing and at 15, 30, and 60 minutes. Visual incompatibility was defined as a change in color, the formation of haze or precipitate, the presence of particles, or the formation of gas in the experimental groups compared with the controls. Disturbances invisible to the naked eye were determined by assessing changes in turbidity of experimental admixtures compared with the controls. RESULTS: None of the admixtures exhibited visual changes when mixed with cisatracurium. Six of the seven admixtures exhibited turbidimetric compatibility with cisatracurium. Pantoprazole admixtures demonstrated a significant difference in turbidimetric assessment between the control and experimental groups when mixed with cisatracurium (p < 0.001). CONCLUSION: Calcium gluconate, diltiazem hydrochloride, esomeprazole, regular insulin, nicardipine hydrochloride, and vasopressin demonstrated physical compatibility with cisatracurium over 60 minutes during simulated Y-site administration. Cisatracurium and pantoprazole should not be coadministered due to a significant difference in turbidity between control and experimental samples.
Asunto(s)
Atracurio/análogos & derivados , Química Farmacéutica , Bloqueantes Neuromusculares/química , Atracurio/administración & dosificación , Atracurio/química , Composición de Medicamentos , Incompatibilidad de Medicamentos , Humanos , Infusiones Intravenosas , Unidades de Cuidados Intensivos , Nefelometría y Turbidimetría , Bloqueantes Neuromusculares/administración & dosificación , Factores de TiempoRESUMEN
Pancuronium is a long-duration neuromuscular blocking drug (NMBD) that has been used in anesthetized rabbits at 0.1 mg/kg. However, there are limited data regarding the time course for recovery from this dose either spontaneously or with pharmacologic reversal. Here we defined the potency, onset, and recovery characteristics for the intermediate-duration NMBD cisatracurium and CW002 (a novel cysteine-inactivated molecule) in the rabbit, and test the hypothesis that these drugs may be alternatives to 0.1 mg/kg pancuronium for survival procedures. New Zealand white rabbits anesthetized with isoflurane were studied in a cross-over design. Potencies of cisatracurium and CW002 were defined as the effective dose for 95% depression of evoked muscle twitch (ED95). Responses to 3×ED95 were used to define onset (time to maximal effect), recovery index (RI; time from 25% to 75% recovery of twitch), and duration (time to complete recovery). Responses to all drugs were determined with and without reversal by neostigmine-glycopyrrolate or L-cysteine. CW002 was 4-fold more potent than was cisatracurium, but their onset, RI, and duration were similar. Pancuronium had similar onset and RI but longer duration, compared with cisatracurium and CW002. Reversal shortened the recovery index and duration for all 3 drugs. At 3×ED95, cisatracurium and CW002 had the same onset as did standard-dose pancuronium, but durations were shorter and more predictable. In addition, CW002 can be reversed without the potential side effects of cholinergic manipulation. We conclude that cisatracurium and CW002 are viable alternatives to pancuronium for survival studies in rabbits.
Asunto(s)
Atracurio/análogos & derivados , Isoquinolinas/administración & dosificación , Bloqueantes Neuromusculares/farmacocinética , Pancuronio/farmacocinética , Animales , Atracurio/administración & dosificación , Atracurio/farmacocinética , Presión Sanguínea/efectos de los fármacos , Estudios Cruzados , Frecuencia Cardíaca/efectos de los fármacos , Isoflurano/administración & dosificación , Masculino , Bloqueantes Neuromusculares/administración & dosificación , Pancuronio/administración & dosificación , ConejosRESUMEN
Acute respiratory distress syndrome (ARDS) is a noncardiogenic pulmonary edema resulting from increased capillary permeability. Numerous pharmacologic therapies have been studied for prevention and treatment of ARDS. Although several pharmacological therapies could improve patient's respiratory function, there have been no controlled studies which clearly demonstrated the clinical benefit for ARDS-related mortality. The role of corticosteroids in ARDS remains controversial. Available evidence is against early administration of high-dose corticosteroids (methylprednisolon 120 mg x kg-1 x day - 1). In contrast, low-dose corticosteroid therapy (methylprednisolon 0.5-2.5mgg kg-1 xday-1)remains controversial. With regard to sivelestat sodium, a specific inhibitor of neutrophil elastase, although the effectiveness in decreasing mortality was not clarified, increases in lung oxygenation and ventilator-free days have consistently been revealed. Other probable pharmacologic therapies for ARDS include continuous infusion of cisatracurium. In conclusion, there are not established drugs for ARDS, and further studies are necessary to reveal the clinical effectiveness of the above mentioned and novel pharmacologic therapies.
Asunto(s)
Anticoagulantes/administración & dosificación , Glicina/análogos & derivados , Metilprednisolona/administración & dosificación , Proteínas Inhibidoras de Proteinasas Secretoras/administración & dosificación , Síndrome de Dificultad Respiratoria/tratamiento farmacológico , Sulfonamidas/administración & dosificación , Animales , Atracurio/administración & dosificación , Atracurio/análogos & derivados , Coagulación Intravascular Diseminada/complicaciones , Coagulación Intravascular Diseminada/tratamiento farmacológico , Glicina/administración & dosificación , Humanos , Metaanálisis como Asunto , Metilprednisolona/efectos adversos , Bloqueantes Neuromusculares/administración & dosificación , Proteína C/administración & dosificación , Quimioterapia por Pulso , Ensayos Clínicos Controlados Aleatorios como Asunto , Proteínas Recombinantes/administración & dosificación , Síndrome de Dificultad Respiratoria/complicacionesRESUMEN
BACKGROUND: The use of low concentrations of volatile anaesthetics with avoidance of opioids may induce intraoperative awareness and adverse haemodynamic responses during Caesarean section. Magnesium is well known to reduce anaesthetic requirements and to block noxious stimuli. We investigated whether i.v. magnesium sulphate modulates anaesthetic depth and analgesic efficacy during Caesarean section. METHODS: Seventy-two patients undergoing Caesarean section were randomly assigned to receive i.v. saline (control group) or magnesium sulphate 30 mg kg(-1) bolus+10 mg kg(-1) h(-1) continuous infusion (Mg 30 group) or 45 mg kg(-1) bolus+15 mg kg(-1) h(-1) continuous infusion (Mg 45 group) after induction. Bispectral index (BIS) value, mean arterial pressure (MAP), and midazolam, fentanyl, and atracurium consumptions were recorded. RESULTS: BIS values [mean (sd)] at 7.5 and 10 min after surgery and before delivery in the control [64 (9), 66 (8), 67 (8), P<0.001] and the Mg 30 groups [62 (8), P<0.01; 64 (7), 63 (9), P<0.001] were higher than in the Mg 45 group [56 (8), 55 (8), 55 (7)]. MAP was greater in the control group (P<0.05) than in the Mg 30 and Mg 45 groups during the pre-delivery period. The magnesium groups required less midazolam (P<0.05), fentanyl (Mg 30, P<0.05; Mg 45, P<0.01), and atracurium (P<0.001) vs the control group. CONCLUSIONS: Preoperative i.v. magnesium sulphate attenuated BIS and arterial pressure increases during the pre-delivery period. Magnesium sulphate can be recommended as an adjuvant during general anaesthesia for Caesarean section to avoid perioperative awareness and pressor response resulting from inadequate anaesthesia, analgesia, or both.
Asunto(s)
Adyuvantes Anestésicos/farmacología , Anestesia General/métodos , Anestesia Obstétrica/métodos , Cesárea , Sulfato de Magnesio/farmacología , Adulto , Analgésicos Opioides/administración & dosificación , Atracurio/administración & dosificación , Presión Sanguínea/efectos de los fármacos , Método Doble Ciego , Esquema de Medicación , Electroencefalografía/efectos de los fármacos , Femenino , Fentanilo/administración & dosificación , Humanos , Hipnóticos y Sedantes/administración & dosificación , Midazolam/administración & dosificación , Monitoreo Intraoperatorio/métodos , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , EmbarazoRESUMEN
During hyperthermic intraperitoneal chemotherapy (HIPEC), we observed a partial recovery from neuromuscular block in a hyperthermic patient after hours of monitored adequate surgical relaxation and continuous infusion of atracurium during normothermia. This recovery is indicative of the higher clearance of atracurium during hyperthermia. This case report emphasizes the clinical relevance of the well-known temperature dependence of the Hofmann elimination of atracurium. Moreover, this report illustrates the importance of monitoring muscle relaxation during HIPEC. Clinicians should be aware that the usual continuous infusion rate of atracurium at 0.3 mg.kg(-1).h(-1) may be inadequate in hyperthermic patients.
Asunto(s)
Atracurio/farmacocinética , Hipertermia Inducida , Fármacos Neuromusculares no Despolarizantes/farmacocinética , Adenocarcinoma/tratamiento farmacológico , Adenocarcinoma/patología , Adenocarcinoma/cirugía , Anestesia Epidural , Antineoplásicos/uso terapéutico , Atracurio/administración & dosificación , Carcinoma/tratamiento farmacológico , Carcinoma/patología , Carcinoma/cirugía , Neoplasias del Colon/tratamiento farmacológico , Neoplasias del Colon/patología , Neoplasias del Colon/cirugía , Femenino , Humanos , Persona de Mediana Edad , Monitoreo Intraoperatorio , Bloqueo Neuromuscular , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Neoplasias Peritoneales/tratamiento farmacológico , Neoplasias Peritoneales/patología , Neoplasias Peritoneales/cirugíaRESUMEN
Introducción: La curva dosis-respuesta acumulativa es un método práctico para evaluar las dosis efectivas de atracurio y rocuronio. Debido a sus características farmacocinéticas, los resultados de dicha curva subestiman la potencia de ambos fármacos en comparación con los que resultan de la administración de dosis únicas. El objetivo de la presente investigación es corregir aquella técnica y hacer las dos estadísticamente equivalentes. Material y métodos: En dos grupos de pacientes electivos se utilizó atracurio o rocuronio para calcular sus potencias por el método de las dosis únicas (n = 45 c/u) o acumulativas (n = 11 c/u). El efecto de cada dosis se determinó por electromiografía, y después de sus transformaciones logaritmo-probits, considerando gamma como la relación probit/log, se obtuvieron las DE 50 y 90 resolviendo la ecuación de Hill para cada sujeto. La técnica acumulativa se corrigió al utilizar las cifras actuales para las dosis y sus efectos, en lugar de los valores acumulativos a partir de la segunda administración. Resultados: Las DE 50 de las técnicas de dosis única, acumulativa y corregida fueron: 172 ± 73, 264 ± 52 y 162 ± 81 mcg/kg respectivamente, cuando se utilizó rocuronio, y 141 ± 61, 193 ± 53 y 141 ± 70 respectivamente, cuando se utilizó atracurio. En el caso de las DE 90 los valores fueron 233 ± 98, 327 ± 65, 254 ± 126 y 222 ± 96, 279 ± 77 y 254 ± 126, en el mismo orden. No se detectaron diferencias significativas entre los métodos de dosis única y corregida, mientras que los valores de las dosis acumulativas fueron significativamente mayores. Discusión y conclusiones: En las condiciones de la presente investigación, una sencilla corrección del método acumulativo reproduce razonable y estadísticamente la potencia del atracurio y del rocuronio evaluada por las dosis únicas.(AU)
Introduction: The cumulative dose-response curve is a practical method to evaluate the effective doses of atracurium and rocuronium. When compared with those obtained by single administrations, the resulting figures underestimate their potency due to pharmacokinetic features. The purpose of this trial is to correct the cumulative technique and to make both statistically equivalent. Material & Methods: Single (n = 45 e/a) or cumulative (n = 11 e/a) doses of atracurium or rocuronium were administered to elective patients and maximal effect assessed by electromyography. A regression line was obtained after log dose-probit effect transformation, and considering gamma as the probit/log ratio, ED 50 and 90 were calculated resolving the Hill equation for each patient. The cumulative technique was corrected by using actual figures instead of cumulative ones, starting at second administration. Results: ED 50 were 172 ± 73, 264 ± 52 y 162 ± 81 mcg/kg as single, cumulative dose or corrected respectively for rocuronium and 141 ± 61, 193 ± 53 y 141 ± 70 for atracurium. ED 90 was 233 ± 98,327 ± 65, 254 ± 126, 222 ± 96, 279 ± 77 y 254 ± 126 in the same order. Non-significant differences between single dose and corrected method were noticed. Cumulative values were significantly larger. Conclusion: In keeping with the conditions of the present trial, a simple correction made to the cumulative method reasonably and statistically reproduces atracurium and rocuronium potencies evaluated by single dose-responses technique.(AU)
IntroduþÒo: A curva dose-resposta acumulativa é um método prático de avaliaþÒo das doses efetivas de atracúrio e rocuronio. Dada suas características farmacocinéticas, os resultados dessa curva subestimam a potÛncia de ambos fármacos em comparaþÒo com os resultados decorrentes da administraþÒo de dose únicas. O objetivo da presente pesquisa é corrigir aquela técnica e tornar as duas estatisticamente equivalentes. Material e métodos: Dois grupos de pacientes eletivos receberam atracúrio ou rocur¶nio com o objetivo de calcular as potÛncias destes fármacos pelo método das doses únicas (n = 45 c/u) ou acumulativas (n = 11 c/u). Foi determinado o efeito de cada dose por eletromiografia, e por transformaþÒo log-probits (considerando gama a relaþÒo probit/log), obtiveram-se as DE 50 e 90 resolvendo a equaþÒo de Hill para cada sujeito. A técnica acumulativa foi corrigida utilizando as cifras atuais para doses e seus efeitos, em lugar dos valores acumulativos, a partir da segunda administraþÒo. Resultados: As DE 50 das técnicas de dose única, acumulativa e corrigida foram: 172 ± 73, 264 ± 52 e 162 ± 81 mcg/kg, respectivamente, quando se utilizou rocur¶nio, e 141 ± 61, 193 ± 53 e 141 ± 70, respectivamente, quando se utilizou atracúrio. No caso das DE 90 os valores foram 233 ± 98, 327 ± 65, 254 ± 126 e 222 ± 96, 279 ± 77 e 254 ± 126, na mesmo ordem. NÒo foram observadas diferenþas significativas entre os métodos (de dose única e corrigida), ao passo que os valores das doses acumulativas foram significativamente maiores. DiscussÒo e conclus§es: Nas condiþ§es da presente pesquisa, uma simples correþÒo do método acumulativo reproduz de forma razoável e estatisticamente as potÛncias do atracúrio e rocuronio avaliadas por doses únicas.(AU)
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Atracurio/administración & dosificación , Atracurio/farmacocinética , Androstanoles/administración & dosificación , Androstanoles/farmacocinética , Relación Dosis-Respuesta a Droga , Bloqueantes Neuromusculares/administración & dosificación , Bloqueantes Neuromusculares/farmacocinética , Dosis Única , Monitoreo Intraoperatorio , Fármacos Neuromusculares no Despolarizantes , Anestesia General/métodos , Cuidados Intraoperatorios , Factores de TiempoRESUMEN
Introducción: La curva dosis-respuesta acumulativa es un método práctico para evaluar las dosis efectivas de atracurio y rocuronio. Debido a sus características farmacocinéticas, los resultados de dicha curva subestiman la potencia de ambos fármacos en comparación con los que resultan de la administración de dosis únicas. El objetivo de la presente investigación es corregir aquella técnica y hacer las dos estadísticamente equivalentes. Material y métodos: En dos grupos de pacientes electivos se utilizó atracurio o rocuronio para calcular sus potencias por el método de las dosis únicas (n = 45 c/u) o acumulativas (n = 11 c/u). El efecto de cada dosis se determinó por electromiografía, y después de sus transformaciones logaritmo-probits, considerando gamma como la relación probit/log, se obtuvieron las DE 50 y 90 resolviendo la ecuación de Hill para cada sujeto. La técnica acumulativa se corrigió al utilizar las cifras actuales para las dosis y sus efectos, en lugar de los valores acumulativos a partir de la segunda administración. Resultados: Las DE 50 de las técnicas de dosis única, acumulativa y corregida fueron: 172 ± 73, 264 ± 52 y 162 ± 81 mcg/kg respectivamente, cuando se utilizó rocuronio, y 141 ± 61, 193 ± 53 y 141 ± 70 respectivamente, cuando se utilizó atracurio. En el caso de las DE 90' los valores fueron 233 ± 98, 327 ± 65, 254 ± 126 y 222 ± 96, 279 ± 77 y 254 ± 126, en el mismo orden. No se detectaron diferencias significativas entre los métodos de dosis única y corregida, mientras que los valores de las dosis acumulativas fueron significativamente mayores. Discusión y conclusiones: En las condiciones de la presente investigación, una sencilla corrección del método acumulativo reproduce razonable y estadísticamente la potencia del atracurio y del rocuronio evaluada por las dosis únicas.
Introduction: The cumulative dose-response curve is a practical method to evaluate the effective doses of atracurium and rocuronium. When compared with those obtained by single administrations, the resulting figures underestimate their potency due to pharmacokinetic features. The purpose of this trial is to correct the cumulative technique and to make both statistically equivalent. Material & Methods: Single (n = 45 e/a) or cumulative (n = 11 e/a) doses of atracurium or rocuronium were administered to elective patients and maximal effect assessed by electromyography. A regression line was obtained after log dose-probit effect transformation, and considering gamma as the probit/log ratio, ED 50 and 90 were calculated resolving the Hill equation for each patient. The cumulative technique was corrected by using actual figures instead of cumulative ones, starting at second administration. Results: ED 50 were 172 ± 73, 264 ± 52 y 162 ± 81 mcg/kg as single, cumulative dose or corrected respectively for rocuronium and 141 ± 61, 193 ± 53 y 141 ± 70 for atracurium. ED 90 was 233 ± 98,327 ± 65, 254 ± 126, 222 ± 96, 279 ± 77 y 254 ± 126 in the same order. Non-significant differences between single dose and corrected method were noticed. Cumulative values were significantly larger. Conclusion: In keeping with the conditions of the present trial, a simple correction made to the cumulative method reasonably and statistically reproduces atracurium and rocuronium potencies evaluated by single dose-responses technique.
Introdução: A curva dose-resposta acumulativa é um método prático de avaliação das doses efetivas de atracúrio e rocuronio. Dada suas características farmacocinéticas, os resultados dessa curva subestimam a potência de ambos fármacos em comparação com os resultados decorrentes da administração de dose únicas. O objetivo da presente pesquisa é corrigir aquela técnica e tornar as duas estatisticamente equivalentes. Material e métodos: Dois grupos de pacientes eletivos receberam atracúrio ou rocurônio com o objetivo de calcular as potências destes fármacos pelo método das doses únicas (n = 45 c/u) ou acumulativas (n = 11 c/u). Foi determinado o efeito de cada dose por eletromiografia, e por transformação log-probits (considerando gama a relação probit/log), obtiveram-se as DE 50 e 90 resolvendo a equação de Hill para cada sujeito. A técnica acumulativa foi corrigida utilizando as cifras atuais para doses e seus efeitos, em lugar dos valores acumulativos, a partir da segunda administração. Resultados: As DE 50 das técnicas de dose única, acumulativa e corrigida foram: 172 ± 73, 264 ± 52 e 162 ± 81 mcg/kg, respectivamente, quando se utilizou rocurônio, e 141 ± 61, 193 ± 53 e 141 ± 70, respectivamente, quando se utilizou atracúrio. No caso das DE 90' os valores foram 233 ± 98, 327 ± 65, 254 ± 126 e 222 ± 96, 279 ± 77 e 254 ± 126, na mesmo ordem. Não foram observadas diferenças significativas entre os métodos (de dose única e corrigida), ao passo que os valores das doses acumulativas foram significativamente maiores. Discussão e conclusões: Nas condições da presente pesquisa, uma simples correção do método acumulativo reproduz de forma razoável e estatisticamente as potências do atracúrio e rocuronio avaliadas por doses únicas.
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Androstanoles/administración & dosificación , Androstanoles/farmacocinética , Atracurio/administración & dosificación , Atracurio/farmacocinética , Relación Dosis-Respuesta a Droga , Bloqueantes Neuromusculares/administración & dosificación , Bloqueantes Neuromusculares/farmacocinética , Anestesia General/métodos , Cuidados Intraoperatorios , Monitoreo Intraoperatorio , Fármacos Neuromusculares no Despolarizantes , Dosis Única , Factores de TiempoRESUMEN
BACKGROUND: Conventional incremental bolus administration of neuromuscular blocking (NMB) drugs is associated with limitations in intraoperative control, potential delays in recovery, and residual blockade in the postanesthetic period. To overcome such limitations, we developed a novel adaptive control computer program, the Neuromuscular Blockade Advisory System (NMBAS). The NMBAS advises the anesthesiologist on the timing and dose of NMB drugs based on a sixth-order Laguerre model and the history of the patient's electromyographic responses. Here, we tested the hypothesis that the use of the NMBAS improves NMB compared to standard care. METHODS: We conducted a prospective, randomized, controlled, blinded, parallel-group, clinical trial with n = 73 patients (ASA physical status I-III) undergoing abdominal surgery under general anesthesia > or =1.5 h with NMB using rocuronium. Patients were allocated to standard care or NMBAS-guided rocuronium administration. The primary outcome variable was the incidence of intraoperative events reflecting inadequate NMB. Secondary outcome variables included train-of-four (TOF) ratios at the end of surgery before reversal, the total doses of rocuronium, reversal agents, anesthetics and other drugs, the incidence of postoperative adverse events, and the incidence of anesthesiologist noncompliance with NMBAS recommendations. RESULTS: Of 73 enrolled patients, n = 30 per group were eligible for analysis. Patient demographics were comparable between the groups. The incidence in total intraoperative events associated with inadequate NMB was significantly lower in the NMBAS group compared to standard care (8/30 vs 19/30; P = 0.004). Mean TOF ratios at the end of surgery before reversal were higher in the NMBAS group (0.59 [95% CI, 0.48-0.69] vs 0.14 [95% CI, 0.04-0.24]; P < 0.0001). Total administered doses of rocuronium, reversal drugs, and other drugs, and the incidence of postoperative adverse events were not different. CONCLUSIONS: Compared to standard practice, NMBAS-guided care was associated with improved NMB quality and higher TOF ratios at the end of surgery, potentially reducing the risk of residual NMB and improving perioperative patient safety.
Asunto(s)
Comités Consultivos/organización & administración , Anestesia General/normas , Bloqueo Neuromuscular/normas , Bloqueantes Neuromusculares/uso terapéutico , Abdomen/cirugía , Adulto , Anciano , Androstanoles/administración & dosificación , Atracurio/administración & dosificación , Femenino , Estado de Salud , Humanos , Complicaciones Intraoperatorias/epidemiología , Complicaciones Intraoperatorias/prevención & control , Masculino , Persona de Mediana Edad , Bloqueantes Neuromusculares/administración & dosificación , Bloqueantes Neuromusculares/normas , Pancuronio/administración & dosificación , Rocuronio , gamma-Ciclodextrinas/administración & dosificaciónRESUMEN
STUDY OBJECTIVE: To describe, in pediatric patients, the effects of three doses of cisatracurium during nitrous oxide-propofol anesthesia and to determine if larger doses result in faster onset time. SETTING: College hospital. SUBJECTS: 75 ASA physical status I and II children, aged 15 to 60 months, undergoing surgery for hypospadias or undescendent testis. INTERVENTIONS: Patients were randomly assigned to one of three groups according to the dose of cisatracurium: Group A = 0.1 mg/kg (two x effective dose), Group B = 0.15 mg/kg (three x effective dose), and Group C = 0.2 mg/kg (4 x effective dose). MEASUREMENTS: Neuromuscular block was assessed with TOF-Guard (Biometer International, Odense, Denmark) accelerometry. Onset time (from cisatracurium injection to maximal depression of time to first twitch), duration of peak effect (time from cisatracurium injection to 5% recovery of time to first twitch), duration of clinical action (time from cisatracurium injection to 25% recovery of time to first twitch), and recovery index (recovery of time to first twitch from 25% to 75%) were recorded. MAIN RESULTS: Cisatracurium had no effect on heart rate or blood pressure at any dose. Compared with Group A, onset times in Groups B and C were shorter; and durations of peak effect and clinical action in Groups B and C were longer (P < 0.01) than those in Group A. There was no difference in recovery index among the three groups. There was no difference in onset times between Groups B and C. Compared with Group B, durations of peak effect and clinical action in Group C were longer (P < 0.05 or P < 0.01). CONCLUSION: Four times the effective dose of cisatracurium did not significantly shorten onset time beyond that produced with three times the effective dose in young children.
Asunto(s)
Anestesia General/métodos , Atracurio/análogos & derivados , Bloqueantes Neuromusculares/administración & dosificación , Anestésicos por Inhalación , Anestésicos Intravenosos , Atracurio/administración & dosificación , Atracurio/farmacología , Preescolar , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Lactante , Masculino , Bloqueantes Neuromusculares/farmacología , Óxido Nitroso , Propofol , Factores de Tiempo , Estimulación Eléctrica Transcutánea del Nervio/estadística & datos numéricosRESUMEN
BACKGROUND: Numerous reports confirm the performance of intradermal tests for the diagnosis of anaphylaxis during anesthesia; however, there is controversy over their diagnostic value regarding the newer neuromuscular blocking agents (NMBAs). METHODS: One hundred eleven healthy volunteers were randomly assigned to receive intradermal injections of two NMBAs, at five increasing concentrations. A concentration was considered as a reactive concentration when it led to a positive reaction in more than 5% of the subjects. These concentrations were compared with the maximal concentration recommended for the diagnosis of sensitization to NMBAs. RESULTS: The maximal nonreactive concentrations were 10 m for suxamethonium; 10 m for pancuronium, vecuronium, rocuronium, and cisatracurium; and 10 m for atracurium and mivacurium. Except for mivacurium, these nonreactive concentrations were close to the maximal concentrations used for the diagnosis of sensitization against NMBAs. For mivacurium, the nonreactive concentrations were higher than the maximal concentration currently recommended in clinical practice. CONCLUSION: The aminosteroidal NMBAs pancuronium, vecuronium, and rocuronium and the benzylisoquinoline cisatracurium have a similar potency to induce a nonspecific skin reactivity. If the criteria for positivity and the maximal concentrations of the commercially available compounds recommended by French practice guidelines are used, the risk of false-positive results is limited, and only minor modifications of these recommendations could be suggested. A slight reduction in the maximal concentration used for rocuronium from 1:100 to 1:200 and an increase from 1:1,000 to 1:200 for mivacurium can be proposed.
Asunto(s)
Hipersensibilidad a las Drogas/diagnóstico , Bloqueantes Neuromusculares/administración & dosificación , Bloqueantes Neuromusculares/efectos adversos , Piel/efectos de los fármacos , Adolescente , Adulto , Androstanoles/administración & dosificación , Androstanoles/efectos adversos , Atracurio/administración & dosificación , Atracurio/efectos adversos , Atracurio/análogos & derivados , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Inyecciones Intradérmicas , Isoquinolinas/administración & dosificación , Isoquinolinas/efectos adversos , Masculino , Persona de Mediana Edad , Mivacurio , Fármacos Neuromusculares Despolarizantes/administración & dosificación , Fármacos Neuromusculares Despolarizantes/efectos adversos , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Fármacos Neuromusculares no Despolarizantes/efectos adversos , Pancuronio/administración & dosificación , Pancuronio/efectos adversos , Valores de Referencia , Rocuronio , Pruebas Cutáneas/métodos , Succinilcolina/administración & dosificación , Succinilcolina/efectos adversos , Bromuro de Vecuronio/administración & dosificación , Bromuro de Vecuronio/efectos adversosRESUMEN
JUSTIFICATIVA E OBJETIVOS: Freqüentemente em cirurgias abdominais, na fase de fechamento da parede, há necessidade de doses adicionais de bloqueador neuromuscular. O objetivo deste estudo foi analisar, na vigência de recuperação parcial do bloqueio neuromuscular induzido pelo pancurônio, o efeito da administração de dose complementar de atracúrio sobre a recuperação espontânea do bloqueio neuromuscular. MÉTODO: Foram estudados 30 pacientes, divididos em dois grupos, 14 pacientes formaram o grupo pancurônio e 16 pacientes, o grupo atracúrio. A função neuromuscular foi monitorizada de forma contínua por acelerometria do músculo adutor do polegar, utilizando a seqüência de quatro estímulos (SQE), através da estimulação supramáxima do nervo ulnar. A indução da anestesia foi feita com propofol, fentanil, pancurônio 0,08 mg.kg-1 e a manutenção com N2O 60 por cento em oxigênio e isoflurano na concentração expirada de 0,5 por cento. Quando a primeira contração da seqüência de quatro estímulos (T1) recuperou 25 por cento, o grupo pancurônio recebeu pancurônio 0,025 mg.kg-1 e o grupo atracúrio, 0,20 mg.kg-1 de atracúrio. Após a dose complementar foram anotados os tempos para recuperação espontânea de T1 igual a 10 por cento, 25 por cento, 75 por cento, do índice de recuperação (IR25-75 por cento) e da relação T4/T1 igual a 0,8. RESULTADOS: Os tempos de recuperação espontânea após dose complementar de pancurônio ou atracúrio não diferiram quando avaliados pela recuperação de T1 em 10 por cento (45,00 ± 15,50 vs 49,69 ± 9,41), 25 por cento (61,64 ± 18,58 vs 64,25 ± 12,51) e 75 por cento (94,00 ± 28,52 vs 84,69 ± 16,50). O IR25-75 por cento (32,36 ± 13,76 vs 20,44 ± 9,24) e o tempo de recuperação da relação T4/T1 = 0,8 (176,86 ± 29,57 vs 141,50 ± 29,57) foram menores no grupo do atracúrio. CONCLUSÕES: Nas condições deste estudo, a complementação com atracúrio não promoveu alteração na recuperação espontânea inicial do bloqueio neuromuscular induzido pelo pancurônio e promoveu diminuição de 20 por cento no tempo de recuperação total.
Asunto(s)
Masculino , Femenino , Adulto , Persona de Mediana Edad , Humanos , Periodo de Recuperación de la Anestesia , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Atracurio/administración & dosificación , Esquema de Medicación , Bloqueo Neuromuscular , Pancuronio/administración & dosificaciónRESUMEN
Introducción: En la práctica clínica se han ensayado diversas formas de administrar los relajantes muculares con vistas a lograr menores tiempos y mejores condiciones de intubación. Objetivos: Determinar las condiciones y el tiempo de intubación que se lograron al utilizar el principio de dosis de cebado en los pacientes quirúrgicos, y evaluar los valores de la altura del twicht en ese período. Material y método: Se realizó una investigación tipo ensayo clínico en 120 pacientes sometidos a cirugía laparoscópica, subdivididos en 2 grupos. La técnica de dosis de cebado se realizó en 60 pacientes. Los relajantes musculares utilizados fueron: pancuronio (Grupo I) dosis de 0,1 mg/kg, vecuronio (Grupo II) 0,1 mg/kg y atracurio (Grupo III) 0,5 mg/kg. A los pacientes de este grupo se les administró el 10 por ciento de la dosis total calculada en los 4 minutos previos a la administración de la dosis restante. Resultados: Al monitorizar la FNM durante la intubación se observó que el tiempo óptimo de intubación, cuando se utilizaron dosis de cebado con atracurio y vecuronio, fue de 112,12 ñ 3,2 y 118ñ1,4 seg. respectivamente, menores al del grupo pancuronio. Las condiciones de intubación obtenidas según los criterios de Lund y Stouner presentaron un 95 por ciento de condiciones excelentes en los grupos II y III y un 60 por ciento en el grupo I. La altura del twitch en igual período fue semejante para los grupos II y III. Al usar dosis de cebado fue de 28,5 ñ 3,1 y 33,1 ñ 0,8 por ciento respectivamente y de 48,1 ñ 1,5 y 49,1 ñ 2,6 por ciento cuando ésta no se utilizó. Estas diferencias resultaron ser estadísticamente significativas (p<0,05). Como consecuencia de esta técnica, en el Grupo II se encontraron, en un 10 por ciento del total, dificultades para respirar y otro 10 por ciento refirió experiencia subjetiva de parálisis respiratoria y en el 20 por ciento del Grupo III se observaron dificultades respiratorias. Tres pacientes del Grupo I y dos de cada Grupo II y III presentaron diplopia. Conclusiones: Las condiciones de intubación fueron más rápidas cuando se empleó dosis de cebado para los tres fármacos, que cuando no se la utilizó. La laringoscopía y la intubación tuvieron mejores condiciones con los fármacos de acción intermedia (vecuronio y atracurio). La altura del twitch disminuyó más cuando se emplearon dosis de cebado en los tres fármacos que cuando no se utilizaron...(AU)
Asunto(s)
Humanos , Masculino , Femenino , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Fármacos Neuromusculares no Despolarizantes/farmacocinética , Fármacos Neuromusculares no Despolarizantes/efectos adversos , Anestesia General/métodos , Atracurio/administración & dosificación , Atracurio/farmacocinética , Pancuronio/administración & dosificación , Pancuronio/efectos adversos , Pancuronio/farmacocinética , Bromuro de Vecuronio/administración & dosificación , Bromuro de Vecuronio/efectos adversos , Bromuro de Vecuronio/farmacocinética , Intubación Intratraqueal/métodos , Laparoscopía , Relación Dosis-Respuesta a Droga , Consentimiento Informado , Selección de Paciente , Distribución AleatoriaRESUMEN
Muscle relaxants are given as part of a rapid-sequence induction to facilitate tracheal intubation. Among all the muscle relaxants available, succinylcholine is the only one with a fast (approximately equal to 1 min) onset and a fast recovery. Therefore it is still the most frequently used muscle relaxant for rapid-sequence induction despite its well-known side-effects. The short duration of action of succinylcholine is, however, no substitute for aggressive airway management in the case of an unexpectedly difficult intubation in order to prevent life-threatening hypoxia. A preoperative assessment of the airway is mandatory in any patient and may indicate the need for using intubation techniques without a muscle relaxant. Rocuronium in large doses (i.e. > or = 1 mg kg-1) is an alternative to succinylcholine in a classical rapid-sequence setting under relatively light anaesthesia. With respect to rapid tracheal intubation, the timing and priming principles offer little advantage over the use of rocuronium in doses of 0.6 mg kg-1 in combination with an appropriate induction technique (i.e. including an opioid) or over the use of larger doses of rocuronium (> or = 1.0 mg kg-1) under relatively light anaesthesia, and may even be potentially harmful. In contrast to rocuronium, the use of rapacuronium in a rapid-sequence setting has been associated with dose-dependent respiratory side-effects that limit its usefulness in doses higher than 1.5 mg kg-1 for this indication.
Asunto(s)
Anestesia/métodos , Intubación Intratraqueal , Bloqueantes Neuromusculares , Bromuro de Vecuronio/análogos & derivados , Androstanoles/administración & dosificación , Androstanoles/farmacología , Anestésicos Intravenosos/administración & dosificación , Atracurio/administración & dosificación , Humanos , Fármacos Neuromusculares Despolarizantes/administración & dosificación , Fármacos Neuromusculares Despolarizantes/efectos adversos , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Fármacos Neuromusculares no Despolarizantes/efectos adversos , Rocuronio , Succinilcolina/administración & dosificación , Succinilcolina/efectos adversos , Bromuro de Vecuronio/administración & dosificación , Bromuro de Vecuronio/efectos adversos , Bromuro de Vecuronio/farmacologíaRESUMEN
The aim of this study was to elucidate the influence of four neuromuscular blocking substances on coronary vascular tone using the model of isolated porcine coronary artery segments. We studied the effects of four muscle relaxants, atracurium, pancuronium, rocuronium, and vecuronium (0.1, 1, and 10 microg mL-1 each), on the contractile response to three vasoconstrictors: acetylcholine, histamine, and serotonin. None of the neuromuscular blocking agents under investigation exerted a significant influence on the vasoconstricting effects of these mediators except for pancuronium, which dose-dependently attenuated acetylcholine-mediated contractions (-10.8% attenuation for 10 microg mL-1 pancuronium, P < 0.05). There was no difference between vessels with intact endothelium and denuded preparations. It is concluded that high-dose pancuronium exerts an antimuscarinic effect in vascular smooth muscle. The other neuromuscular agents studied do not alter vascular reactivity of isolated porcine coronary arteries.
Asunto(s)
Vasos Coronarios/efectos de los fármacos , Músculo Liso Vascular/efectos de los fármacos , Fármacos Neuromusculares no Despolarizantes/farmacología , Acetilcolina/farmacología , Androstanoles/administración & dosificación , Androstanoles/farmacología , Animales , Atracurio/administración & dosificación , Atracurio/farmacología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Endotelio Vascular/efectos de los fármacos , Histamina/farmacología , Antagonistas Muscarínicos/farmacología , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Pancuronio/administración & dosificación , Pancuronio/farmacología , Rocuronio , Serotonina/farmacología , Estadística como Asunto , Porcinos , Vasoconstricción/efectos de los fármacos , Vasoconstrictores/farmacología , Vasodilatadores/administración & dosificación , Vasodilatadores/farmacología , Bromuro de Vecuronio/administración & dosificación , Bromuro de Vecuronio/farmacologíaRESUMEN
OBJECTIVE: To quantify the effects of neuromuscular blockade (NMB) on energy expenditure for intubated, mechanically ventilated, critically ill children. DESIGN: A prospective, unblinded clinical study. Each subject was studied twice, before and after establishment of NMB. SETTING: A tertiary care pediatric intensive care unit. PATIENTS: Critically ill children undergoing mechanical ventilation and receiving ongoing sedation were eligible, if they had a cuffed endotracheal tube and were physiologically stable. INTERVENTIONS: A total of 20 children (age, 1 to 15 yrs) were studied in an unblinded, crossover fashion. All were mechanically ventilated via a cuffed endotracheal tube, with ventilator rate and tidal volume adequate to provide complete ventilation, and F(IO2) <0.6. Absence of gas leak around the endotracheal tube was assured, and all patients were sedated using continuous infusions of midazolam and/or fentanyl; no changes in ventilator settings, nutritional input, or inotropic drug dose were permitted during the study period. Each patient underwent indirect calorimetry immediately before establishment of NMB. NMB was then induced, and indirect calorimetry was repeated. Complete blockade was verified using a peripheral nerve stimulator. In each case, the two sets of measurements were completed within a 1-hr period. MEASUREMENTS AND MAIN RESULTS: Data analyzed included identifying and diagnostic information, oxygen consumption, and carbon dioxide production. Energy expenditure was calculated using standard formulas. Oxygen consumption and energy expenditure values obtained before and after the establishment of NMB were compared by using paired Student's t-test. NMB reduced oxygen consumption from 6.54+/-0.49 mL/kg/min to 5.90+/-0.40 ml/kg/min, and energy expenditure was reduced from 46.5+/-3.7 kcal/kg/24 hrs to 41.0+/-2.8 kcal/kg/24 hrs (p < .001 in each case). The reduction in oxygen consumption was 8.7+/-1.7%, and that in energy expenditure 10.3+/-1.8%, of pre-NMB values, respectively. CONCLUSION: NMB significantly reduces oxygen consumption and energy expenditure in critically ill children who are sedated and mechanically ventilated; the degree of reduction is small.
Asunto(s)
Sedación Consciente , Metabolismo Energético/efectos de los fármacos , Intubación Intratraqueal , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Consumo de Oxígeno/efectos de los fármacos , Respiración Artificial , Adolescente , Atracurio/administración & dosificación , Atracurio/efectos adversos , Calorimetría Indirecta , Niño , Preescolar , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Femenino , Humanos , Lactante , Unidades de Cuidado Intensivo Pediátrico , Masculino , Fármacos Neuromusculares no Despolarizantes/efectos adversos , Pancuronio/administración & dosificación , Pancuronio/efectos adversos , Bromuro de Vecuronio/administración & dosificación , Bromuro de Vecuronio/efectos adversosRESUMEN
Compared to atracurium, cisatracurium releases less laudanosine and histamine, but it has a longer onset time. The primary objective of this study was a blinded, randomized comparison of intubation scores and onset times of a threefold ED 95 of cisatracurium using the priming technique with two priming substances cisatracurium itself and pancuronium. To test the effect of priming with cisatracurium or pancuronium on the onset of cisatracurium, 45 patients were anaesthetised with 0.15-0.25 mg/kg alfentanil, 0.25-0.3 mg/kg edomidate i.v. and O2/N2O, and were randomisely divided into one of three groups. After induction, 15 patients were primed with sodium chloride and thereafter received 0.15 mg/kg cisatracurium, 15 patients were primed with 0.01 mg/kg cisatracurium, another 15 patients were primed with 0.015 mg/kg pancuronium and the last two groups received 0.14 mg/kg cisatracurium three minutes later. Neuromuscular response was monitored by adductor pollicis electromyogram (EMG) by stimulating in a TOF pattern. Times for T1 reduction to 75%, 50%, 25% and 0% and T1 recovery to 25% were taken. Intubation was performed 120 seconds after the main relaxant dose and scored in four grades. The two priming groups showed a significantly faster onset of neuromuscular blockade than the control group (cisatracurium priming group: T1 = 0: 178.4 +/- 16.3 sec., pancuronium priming group 171.2 +/- 15.3 sec. vs. control group: T1 = 0: 205.5 +/- 18.9 sec.). Both primed groups showed no significantly better intubation scores, compared with the control group. Using the priming principle, cisatracurium will give good intubation scores 120 seconds after injection with a clinical duration profile comparable to an equipotent dose of atracurium.
Asunto(s)
Anestesia General , Atracurio/análogos & derivados , Intubación Intratraqueal , Bloqueantes Neuromusculares/administración & dosificación , Adulto , Anciano , Atracurio/administración & dosificación , Atracurio/efectos adversos , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Esquema de Medicación , Electromiografía/efectos de los fármacos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Bloqueantes Neuromusculares/efectos adversos , Pancuronio/administración & dosificación , Pancuronio/efectos adversosRESUMEN
BACKGROUND: The times to peak effect of rocuronium, vecuronium, cisatracurium, mivacurium, and succinylcholine were evaluated to confirm that the correlation between potency and onset time observed for long-acting relaxants also held for drugs of intermediate and short duration. METHODS: The authors recruited 99 patients classified as American Society of Anesthesiologists physical status score 1 or 2 for the study. After anesthesia was induced, tracheal intubation was accomplished without relaxants. Anesthesia was maintained with nitrous oxide and 3% or 4% end-tidal desflurane plus intravenous narcotic supplementation. The evoked electromyographic response to single stimuli administered at 0.10 Hz was recorded continuously. Drug doses were selected to produce approximately 95% twitch depression. If peak twitch depression did not fall in the range of 90% to 98%, the patient was excluded from the study. The time to 50% to 90% of peak effect was plotted as a function of the administered dose. RESULTS: There was no difference in the onset profiles of mivacurium and vecuronium, or in the time to 50% of peak effect between succinylcholine and rocuronium. For all other parameters, onset times ranked as follows: succinylcholine < rocuronium < vecuronium-mivacurium < cisatracurium (P < 0.05). When the log of the ED95 in micromoles per kilogram for all five drugs was plotted against the log of onset time to 50% peak effect, the R2 value for the best fit line was more than 0.98. CONCLUSIONS: The inverse correlation between the molar potency and speed of onset previously described for agents of long duration also applies to nondepolarizing agents of intermediate and short duration. The onset time of succinylcholine also appears to be compatible with this relation.
Asunto(s)
Bloqueo Neuromuscular , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Adulto , Androstanoles/administración & dosificación , Atracurio/administración & dosificación , Atracurio/análogos & derivados , Femenino , Humanos , Masculino , Persona de Mediana Edad , Rocuronio , Succinilcolina/administración & dosificación , Factores de Tiempo , Bromuro de Vecuronio/administración & dosificaciónRESUMEN
Effects of nondepolarizing myorelaxants pancuronium, arduan, and tracrium were studied during surgery in 347 children with thermal injuries aged from several months to 15 years. Nondepolarizing myorelaxants are drugs of choice for providing myoplegia in children operated on for thermal injuries. The optimal initial dose of these agents in children with burns is 30-50% higher than the recommended dose and depends on the size of the lesion. For controllable myoplegia, the doses of subsequent injections are to be 1.-5-2 times lowered in comparison with the initial dose. The effects of pancuronium and arduan depend on the hepatorenal function. Tracrium ensures sufficient controllable myorelaxation in children with burns even in cases with hepatorenal dysfunction.